0001592052-24-000003.txt : 20240108 0001592052-24-000003.hdr.sgml : 20240108 20240108160106 ACCESSION NUMBER: 0001592052-24-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 EFFECTIVENESS DATE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Centrexion Therapeutics Corp CENTRAL INDEX KEY: 0001592052 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320402377 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-501850 FILM NUMBER: 24520003 BUSINESS ADDRESS: STREET 1: 200 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: (617) 837-6911 MAIL ADDRESS: STREET 1: 200 STATE STREET STREET 2: 6TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Centrexion Corp DATE OF NAME CHANGE: 20131114 D 1 primary_doc.xml X0708 D LIVE 0001592052 Centrexion Therapeutics Corp 200 STATE STREET 6TH FLOOR BOSTON MA MASSACHUSETTS 02109 (617) 837-6911 DELAWARE Centrexion Corp Corporation true Jeffrey B. Kindler 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Director James N. Campbell, M.D. 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Director Randall M. Stevens 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Michael J. Ward 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Executive Officer Sol Barer, Ph.D. 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Director Colin Hill 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Director J.C. Lopez, M.D. 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Director Joseph R. Swedish 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Director Shawn Tomasello 200 State Street, 6th Floor Boston MA MASSACHUSETTS 02109 Director Biotechnology Decline to Disclose 06b false 2023-12-28 false true true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue 16th Floor New York NY NEW YORK 10022 All States false 12859762 3255467 9604295 false 116 1283206 true 0 The compensation payable to Maxim Group LLC under the total offering amount is estimated to consist of (i) a cash fee (listed above) and (ii) a warrant to purchase up to 855,470 shares of Centrexion's common stock. 0 false Centrexion Therapeutics Corp /s/ Michael Ward Michael Ward Chief Financial Officer, Treasurer, and Secretary 2024-01-08